Swedisg drugmaker Egetis's Q1 revenue rises 9% on  Emcitate sales in Europe

Egetis Therapeutics AB (publ)

29/04/2026 06:43

Overview

Sweden rare disease drugmaker's Q1 revenue rose 9% at CER

Adjusted EPS for Q1 was SEK -0.2

FDA accepted NDA for Emcitate, granted priority review with PDUFA date set for Sept 28, 2026

Outlook

Company expects FDA decision on Emcitate by September 28, 2026

Egetis is accelerating U.S. launch preparations for Emcitate ahead of potential approval

Company aims to optimize pricing and reimbursement and continue Emcitate launch in Europe

Result Drivers

EUROPEAN LAUNCH - Revenue growth attributed to Emcitate sales in Europe, with Germany and Italy highlighted as key markets

NAMED PATIENT SALES - Additional revenue generated from named patient sales in Poland and Turkey

Company press release: ID:nMFN145NVv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
SEK 13.40 mln
SEK 21.85 mln (2 Analysts)
Q1 Adjusted EPS
-SEK 0.20


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Egetis Therapeutics AB (publ) is SEK14.00, about 141.8% above its April 28 closing price of SEK5.79

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)